»
Cell Press Reviews: Cancer Therapeutics
 
 

Cell Press Reviews: Cancer Therapeutics, 1st Edition

 
Cell Press Reviews: Cancer Therapeutics, 1st Edition,ISBN9780124201927
 
 
 

AP Cell

9780124201927

9780127999173

322

235 X 191

Brings together topical review articles recently published in Cell Press journals, to assist both experts and those new to the field in understanding the current state and future direction of cancer therapy.

Print Book + eBook

USD 35.94
USD 59.90

Buy both together and save 40%

Print Book

Paperback

In Stock

Estimated Delivery Time
USD 34.95

eBook
eBook Overview

DRM-free included formats : EPUB, Mobi (for Kindle), PDF

USD 24.95
Add to Cart
 
 

Key Features

• Provides timely, comprehensive articles on a wide range of topics in cancer therapeutics
• Offers insight from experts on genetic, molecular, and cellular aspects of cancer therapy
• Features reviews on basic science advances translated into drug discovery and therapeutic approaches
• Includes articles originally published in Cell, Cancer Cell, Trends in Genetics, Trends in Molecular Medicine, and Trends in Pharmacological Sciences

Description

Cell Press Reviews: Cancer Therapeutics informs, inspires, and connects cancer researchers at all stages in their careers with timely, comprehensive reviews written by leaders in the field and curated by Cell Press editors. The publicatio offers a broad view of some of the most compelling topics in cancer therapeutics including:

  • Genetic approaches for personal oncology
  • Targeting epigenetic dysregulation and protein interaction networks
  • Vaccines and antibodies in cancer immunotherapy
  • Tumor heterogeneity and chemotherapy resistance
  • Tumor associated macrophages in anticancer treatment

Contributions come from leading voices in the field, including:
- Daniel A. Haber, Director of Massachusetts General Hospital Cancer Center and Professor at Harvard Medical School
- Tony Kouzarides, Professor at the University of Cambridge, Deputy Director of the Wellcome Trust/Cancer Research UK Gurdon Institute, and a founder of the cancer drug discovery company Chroma Therapeutics
- Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, President of the American Association for Cancer Research, member of the presidentially appointed National Cancer Advisory Board, and recipient of the 2013 Breakthrough Prize in Life Sciences

Cell Press Reviews: Cancer Therapeutics is part of the Cell Press Reviews series, which features reviews published in Cell Press primary research and Trends reviews journals.

Readership

Academic, medical researchers, and students in cancer biology, and cancer prevention/therapeutics, including cell biologists, biological chemists, geneticists, pharmacologists, oncologists, and radiation oncologists.

Cell Press Reviews: Cancer Therapeutics, 1st Edition

About Cell Press

Contributors

Preface

Chapter 1. The Evolving War on Cancer

Acknowledgments

Summary

Introduction

Breaking the Cancer War Stalemate

Drawing from Somatic Cancer Genetics to Find Therapeutic Targets

Challenging Medicinal Chemistry to Design New Classes of Inhibitors

Redesigning Cancer Clinical Trials: Genotype First, Monitor in Real Time

The Next Steps in the War on Cancer

References

Chapter 2. Can We Deconstruct Cancer, One Patient at a Time?

Acknowledgments

Summary

Cancer Treatment in the Age of Omics

Cancer as a Black Box

Deconstructing Cancer, One Patient at a Time

The Road Ahead

Concluding Remarks

References

Chapter 3. The Genetic Basis for Cancer Treatment Decisions

Acknowledgments

Summary

Introduction

Framework Requirements for Evaluating the Genetic Basis for Cancer Treatment

Patient Recruitment and Informed Consent

Tissue Requirements: Quantity, Quality, Processing, and Timing

Genomic Technologies and Data Management

Reporting Data to Clinicians and Patients

Monitoring and Evaluating the Utility of Clinical Genomics

Data Sharing

Implications for Drug Development

Implications for Regulatory Bodies

Implications for Patients, Healthcare Providers, and Payers

Conclusions

References

Chapter 4. Cancer Epigenetics: From Mechanism to Therapy

Acknowledgments

Summary

Introduction

Characterizing the Epigenome

Epigenetics and the Cancer Connection

Epigenetic Pathways Connected to Cancer

Perspective and Conclusions

References

Chapter 5. Converting Cancer Therapies into Cures: Lessons from Infectious Diseases

Acknowledgments

Summary

Introduction

Mutational Mechanisms of Resistance

Nonmutational Resistance Mechanisms

Overcoming Resistance

Exceptions: Examples of Successful Monotherapy

Precision Diagnostics: Essential for Targeted Cancer Drugs, Missed Opportunity for Antibacterials

Conclusions and Challenges

References

Chapter 6. Antibody-Based Immunotherapy of Cancer

Acknowledgments

Summary

Introduction

Manipulating Antibody Structure

Stimulating Persistent Immunity

Modulating the Amplitude of Immune Responses

Immunoconjugates: Targeting Cytotoxic Agents

A Longer-Term View

Supplemental Information

Web Resources

References

Chapter 7. Macrophage Regulation of Tumor Responses to Anticancer Therapies

Acknowledgments

Summary

Introduction

Tumor-Associated Macrophages

Macrophage Involvement in Tumor Responses to Therapy

Concluding Remarks: Implications for Cancer Treatment

References

Chapter 8. Recombinant Viral Vaccines for Cancer

Acknowledgments

Summary

Cancer Immunity

Recombinant Viral Vaccines Expressing TAAs

Recombinant Viral Vaccines Expressing Tumour-Associated Antigens and Immunomodulatory Molecules

IT Vaccination to Enhance Immune Activation

Oncolytic Viral Vaccines

Granulocyte Macrophage Colony Stimulating Factor

Modulating the Tumour Immune Microenvironment

Implications for the Future of Cancer Vaccines

References

Chapter 9. Dynamics of Targeted Cancer Therapy

Summary

Targeted Cancer Therapy

Modeling the Evolution of Resistance to Cancer Therapy

Effects of Density Dependence on the Evolution of Resistance

Applications and Extensions

Concluding Remarks and Future Perspectives

Appendix A Supplementary Material

References

Chapter 10. Targeting Protein–Protein Interactions as an Anticancer Strategy

Acknowledgment

Summary

Rising Interest in Targeting PPIs

PPI interfaces Constitute Basic Units in Oncogenic Signaling Networks

OVERCOMING CHALLENGES and Current Strategies for Targeting of PPIs

Clinical Validation of PPI Targeting in Cancer

Emerging Opportunities for Targeting of PPIs

Concluding Remarks

References

Chapter 11. Targeting the RAS Pathway in Melanoma

Acknowledgments

Summary

Current Therapies for Melanoma

The Central Melanoma Axis and Therapeutic Targets

Concluding Remarks

References

Chapter 12. Targeting Tumor Cell Motility as a Strategy against Invasion and Metastasis

Acknowledgments

Summary

Basic Mechanisms of Tumor Dissemination

Motility Cascade

Extracellular Regulators of Migration

Potential Interventional Opportunities

Concluding Remarks

References

Chapter 13. The Valley of Death in Anticancer Drug Development: A Reassessment

Acknowledgments

Summary

The Valley of Death

The Tumor Microenvironment

The Impact of Exposure Time

Choice of Preclinical Model

Drug Delivery to Tumors

Changing Clinical Practice

Some Paths Forward

Concluding Remarks

References

Chapter 14. Metformin and Cancer: From the Old Medicine Cabinet to Pharmacological Pitfalls and Prospects

Acknowledgments

Summary

The Past and Present of Metformin

Rationale for Cancer Prevention with Metformin

Role of Metformin in Gluconeogenesis and its Link to Chemoprevention

Influence of Metformin Disposition on Cancer Prevention

Concluding Remarks

References

Chapter 15. Curing APL through PML/RARA Degradation by As2O3

Acknowledgments

Summary

Both Poison and Cure

APL Response to Therapies

A Key Role of PML/RARA Degradation in Therapy Response

How does Arsenic Induce Degradation of PML and PML/RARA?

How does Arsenic Trigger PML Sumoylation?

What is the Role for PML NBs in APL Therapy?

Are there Other Arsenic-Sensitive Diseases?

Concluding Remarks

References

Glossary

Chapter 16. A Snapshot of Chemoresistance to PARP Inhibitors

Acknowledgments

Summary

Exploiting Synthetic Lethality for Targeted Therapy

PIR: Experimental and Clinical Evidence

Restoration of BRCA Function: an Inevitable Drawback of PARPi?

P-Glycoprotein Upregulation: Auto-Defeating Effects of PARPi

Further Considerations

Concluding Remarks

References

Index

Quotes and reviews

"...offers the most up-to-date insights into how genetics influences treatnent decisions and how the immune system can be employed to battle cancer, and describes the current state-of-the-art in drug discovery and targeted treatments."--Anticancer Research, January 2015

 
 
Free Shipping
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us